热门资讯> 正文

Mineralys Therapeutics股票发行价为1.5亿美元

2026-06-03 18:31

Mineralys Therapeutics (MLYS) has priced an offering of 5.66M shares of its common stock at a price of $26.50 per share.
The gross proceeds from the offering are expected to be around $150M. Mineralys plans to use the net proceeds to fund a portion of the $200M upfront payment for the repurchase of the royalty obligation under its license agreement with Tanabe Pharma.
The sale is expected to close on or about June 4, 2026, subject to the satisfaction of customary closing conditions.
BofA Securities, Goldman Sachs & Co. and Evercore ISI are acting as joint book-running managers for the offering.

More on Mineralys Therapeutics

Mineralys Therapeutics, Inc. (MLYS) Presents at 35th European Meeting on Hypertension and Cardiovascular Protection - Slideshow
Mineralys Therapeutics, Inc. (MLYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Mineralys: 'Hold' As Hypertension OSA Data Barely Delivers And AstraZeneca On The Move
Mineralys outlines lorundrostat U.S. launch plans ahead of December 22, 2026 PDUFA
Mineralys Therapeutics GAAP EPS of -$0.47 misses by $0.02

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。